Welcome to our dedicated page for Caris Life Sciences news (Ticker: CAI), a resource for investors and traders seeking the latest updates and insights on Caris Life Sciences stock.
Caris Life Sciences, Inc. develops and commercializes AI-enabled precision medicine solutions built around comprehensive molecular profiling, next-generation sequencing and machine learning. The company’s diagnostics and data platform use Whole Genome, Whole Exome and Whole Transcriptome Sequencing, a multimodal clinico-genomic database and high-performance computing to support early detection, diagnosis, monitoring, therapy selection and drug development.
Company announcements commonly address molecular profiling services, clinical therapy selection volume, product launches and regulatory or reimbursement actions for tests such as Caris Assure, Caris MI Clarity and Caris ChromoSeq. Other recurring developments include peer-reviewed validation of Caris AI Insights, Caris Precision Oncology Alliance collaborations, conference presentations and quarterly financial results.
Caris Life Sciences (NASDAQ: CAI) added two proprietary Caris AI Insights signatures predicting brain metastases risk in breast cancer and non-small cell lung cancer (NSCLC), bringing its total to seven.
The signatures were trained on 12,994 NSCLC and 3,371 breast cases and use WES/WTS data; MI Cancer Seek orders include the report at no extra cost. Caris reports its multimodal dataset exceeds 500,000 patients tested and notes an ongoing study with the Caris Precision Oncology Alliance to highlight the risk‑prediction approach.
Caris Life Sciences (NASDAQ: CAI) will present six oncology studies at the AACR Annual Meeting, April 17-22, 2026, in San Diego. The posters use Caris' multimodal database (WES, WTS, IHC, real-world clinical data) across breast, prostate, lung and colorectal cancers.
Research highlights will be onsite at booth #1423; full abstracts follow the presentations on the company website.
Caris Life Sciences (NASDAQ: CAI) emphasized the importance of DPYD testing for colorectal cancer patients during Colorectal Cancer Awareness Month on March 24, 2026. The company noted the FDA updated safety labeling for capecitabine and 5-FU and incorporated DPYD reporting into its blood-based Caris Assure Whole Exome and Whole Transcriptome Sequencing assay.
This integration enables clinicians to detect inherited DPYD variants from a single blood draw, aiming to inform fluoropyrimidine therapy decisions and reduce risk of severe toxicity before treatment begins.
Caris Life Sciences (NASDAQ: CAI) published a JAMA Network Open study (March 20, 2026) showing its GPSai algorithm reclassified cancer diagnoses among lung squamous cell carcinoma submissions. Of 3,958 cases, GPSai identified 123 as metastases from other primaries; 88 patients (71.5%) had guideline-preferred first-line therapy changes. Caris reports GPSai has overturned 3,857 diagnoses since January 2024. The GPSai capability is included in MI Cancer Seek and MI Tumor Seek; MI Cancer Seek received FDA approval November 2024.
Caris Life Sciences (NASDAQ: CAI) introduced a new platinum resistance AI signature to its Caris AI Insights portfolio on March 16, 2026. The model predicts early platinum resistance in high-grade serous ovarian cancer (HGSOC) using Whole Exome and Whole Transcriptome sequencing plus clinical data, providing a risk score, platinum sensitive/platinum resistant prediction and supporting Kaplan-Meier curves. The insight is available now by request through the Caris Molecular Tumor Board Report when ordering the tissue-based test MI Cancer Seek. Caris previously received FDA approval for MI Cancer Seek in November 2024.
Caris Life Sciences (NASDAQ: CAI) will present five studies at the 2026 USCAP Annual Meeting in San Antonio, March 21–26, 2026. Presentations include one oral session and four posters across sarcomas, melanoma and GIST, using Caris' multimodal WES/WTS/IHC and real-world database. Research will be available at booth #512 and full abstracts will be posted on the company website after presentations.
Caris Life Sciences (NASDAQ: CAI) announced on March 9, 2026 the launch of a proprietary Caris AI Insights signature for pancreatic ductal adenocarcinoma (PDAC) included in the Caris Molecular Tumor Board Report.
The AI signature uses WES, WTS and clinical data from a >550,000-patient real-world dataset to help guide first-line regimen choice (FOLFIRINOX vs gemcitabine/nab-paclitaxel) and identify candidates for treatment de-escalation. Caris notes prior FDA approval (Nov 2024) of its MI Cancer Seek tissue assay; a publication on the PDAC signature is expected in 2026.
Caris Life Sciences (NASDAQ: CAI) announced an interim readout of Achieve 1 for its Caris Detect multi-cancer early detection test on Feb 26, 2026. The interim dataset (2,122 samples) showed stage I sensitivity 56.8%, stage II 70.1%, and overall Stage I–II sensitivity 61.3%.
The study reported specificity 99.1% in an asymptomatic screening subgroup (n=121) and 95.3% in the undiagnosed population (n=1,505). A blinded validation (~865 samples) is in process with results expected later in Q1 2026.
Caris Life Sciences (NASDAQ: CAI) reported an interim readout of Achieve 1 for Caris Detect, its multi-cancer early detection blood test using ultra-deep Whole Genome Sequencing and AI. The interim dataset (n=2,122) showed Stage I sensitivity 56.8%, Stage I-II sensitivity 61.3% and specificity 99.1% in an asymptomatic screening subgroup.
Caris held ~865 samples for a blinded validation planned for Q1 2026; development of an updated assay with Whole Transcriptome Sequencing is underway.
Caris Life Sciences (NASDAQ: CAI) reported strong 2025 results with $812.0M revenue, up 97% year-over-year, and Q4 revenue of $292.9M (+125%). Gross margin improved to 66% for FY 2025. The company reported positive Adjusted EBITDA $137.7M and positive free cash flow $66.9M. Caris expects 2026 revenue of $1.0B–$1.02B and reiterated plans to launch Caris Detect in H1 2026.